SLC22A2 (OCT2)
SLC22A2proteinSLC22A2 genetic variation modulates cardiomyocyte acylcarnitine uptake and reperfusion-injury sensitivity.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleTransporter of acylcarnitines in cardiomyocyte; MI susceptibility locus.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000112499
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Human genetic evidence
2
GWAS associations
Traits: myocardial infarction
Literature evidence(2)
- Shared Genetic Liability Between Heart Failure and Myocardial Infarction Revealed by Genome-Wide Cross-Trait Analysis.Journal of cardiovascular pharmacology and therapeutics · 2026 · PMID 42141940 · doi
- Targeting long-chain acylcarnitine accumulation to protect cardiac mitochondrial homeostasis after complete revascularization.Cell reports. Medicine · 2025 · PMID 41406945 · doi